Next Article in Journal
A Novel Computational Model for Detecting the Severity of Inflammation in Confirmed COVID-19 Patients Using Chest X-ray Images
Previous Article in Journal
Symmetric Reconstruction of Functional Liver Segments and Cross-Individual Correspondence of Hepatectomy
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Diagnostics
Volume 11
Issue 5
10.3390/diagnostics11050854
Review Report
diagnostics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Article
Peer-Review Record

Low Skeletal Muscle Mass Is a Risk Factor for Subclinical Atherosclerosis in Patients with Nonalcoholic Fatty Liver Disease

Diagnostics 2021, 11(5), 854; https://doi.org/10.3390/diagnostics11050854
by Min-Kyu Kang and Jung-Gil Park *
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Diagnostics 2021, 11(5), 854; https://doi.org/10.3390/diagnostics11050854
Submission received: 5 April 2021 / Revised: 4 May 2021 / Accepted: 8 May 2021 / Published: 10 May 2021
(This article belongs to the Section Pathology and Molecular Diagnostics)

Round 1

Reviewer 1 Report

  1. This is a nicely written manuscript on an important topic, NAFLD.
  2. What did the “one study” on line 52 find, and how is this investigation novel and set to advance the field? This should be described in the introduction and lead to a directional hypothesis statement.
  3. Inclusion of a biostatistician would provide rigor to this study.
  4. Are these individuals technically obese with mean BMI = 28? It needs to be included in the flow chart in figure 1 the number of obese patients used.
  5. What about comparison of obese vs. non-obese for cIMT and carotid plaques in NAFLD patients?
  6. It is not exactly clear what “LSMM_BMI” and “Non-LSMM_BMI” mean in table 1?
  7. What are results in patients without NAFLD but with LSMM?
  8. Do any of the patients have clinically defined sarcopenia? The rationale in the introduction is based on sarcopenia.
  9. Metabolic factors do not seem to be the mechanism linking LSMM and CVD. But, in the discussion, it is mentioned that insulin resistance-mediated inflammation is a mechanism. Were insulin levels associated with anything here? Also, CRP levels were not different between here, are there any other inflammatory factors that should be looked at regarding this mechanistic link?

Author Response

Thank you very much for the meticulous review.

The response to the reviewer's comment has been summarized and attached as a word file. Please see the attachment.

Author Response File: Author Response.docx

Reviewer 2 Report

To the authors of the manuscript,

I have found the association between atherosclerosis and sarcopenia. After revising the work, I recommend to accept it with MINOR CHANGES.

My main concern is that the possible relationship between dietary or lifestyle habits and sarcopenia development. At least it should be included in the discussion.

Author Response

Thank you very much for the meticulous review.

The response to the reviewer's comment has been summarized and attached as a word file. Please see the attachment.

Author Response File: Author Response.docx

Round 2

Reviewer 1 Report

The authors have adequately addressed my previous concerns.

Back to TopTop